Zymeworks inks new antibody licensing deal with Merck

Canadian biotech firm Zymeworks (NYSE: ZYME) saw its share gain 5% in after-hours trading yesterday, after announcing it has signed a new license deal with long-time partner, Merck & Co (NYSE: MRK) to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.